Loading...
LALPATHLAB logo

Dr. Lal PathLabs LimitedNSEI:LALPATHLAB Voorraadrapport

Marktkapitalisatie ₹261.2b
Prijs aandeel
₹3.13k
Mijn reële waarde
₹3.31k
5.5% ondergewaardeerd intrinsieke korting
1Y-10.5%
7D-2.1%
Portefeuillewaarde
​
Bekijk

Dr. Lal PathLabs Limited

NSEI:LALPATHLAB Voorraadrapport

Marktkapitalisatie: ₹261.2b

Dr. Lal PathLabs (LALPATHLAB) Aandelenoverzicht

Dr. Lal PathLabs Limited beheert laboratoria voor het uitvoeren van pathologisch onderzoek in India en daarbuiten. Meer informatie

LALPATHLAB fundamentele analyse
Sneeuwvlok Score
Waardering1/6
Toekomstige groei3/6
Prestaties in het verleden6/6
Financiële gezondheid6/6
Dividenden3/6

Beloningen

De winst zal naar verwachting met 11.53% per jaar groeien

De winst groeide het afgelopen jaar met 34.5%

Risicoanalyse

Onstabiel dividend track record


LALPATHLAB Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

LALPATHLAB logo
Dr. Lal PathLabs

Digital Health Trends Will Squeeze Margins Yet Allow Modest Recovery

Key Takeaways Rapid digitalization and new entrants in diagnostics threaten Dr. Lal PathLabs' traditional business model, risking loss of patients and profitability from heightened competition. Ongoing integration issues with acquired labs, combined with intensifying pricing pressures and regulatory risks, could hinder successful expansion and sustained earnings growth.
View narrative
₹2.37k
FV
32.1% overgewaardeerd intrinsieke korting
11.31%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 1 month ago author updated this narrative
LALPATHLAB logo
Dr. Lal PathLabs

Ayushman Bharat And Chronic Trends Will Expand Diagnostics Access

Key Takeaways Expansion into underserved regions, rising disease incidence, and industry formalization are driving sustained volume and revenue growth with higher market share. Investments in technology, specialized high-margin offerings, and operational scale are supporting profitability and improving overall margin profile despite competition.
View narrative
₹3.28k
FV
4.8% ondergewaardeerd intrinsieke korting
12.56%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
about 1 month ago author updated this narrative
LALPATHLAB logo
Dr. Lal PathLabs

Expanding Middle Class And Digital Health Will Boost Diagnostics

Key Takeaways Rapid rural expansion, mobile tech adoption, and rising health awareness could drive much greater patient volume and revenue growth than anticipated. Early leadership in specialized diagnostics and a strong financial position may yield premium pricing, market expansion, and robust, sustainable earnings growth.
View narrative
₹4.02k
FV
22.2% ondergewaardeerd intrinsieke korting
13.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
24 days ago author updated this narrative
View Stock Community

Dr. Lal PathLabs Limited Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Dr. Lal PathLabs
Historische aandelenkoersen
Huidige aandelenkoers₹3,127.70
52 Week Hoogtepunt₹3,653.95
52 Week Laag₹2,293.55
Bèta0.062
1 maand verandering-5.78%
3 maanden verandering9.78%
1 Jaar Verandering-10.52%
3 jaar verandering28.09%
5 jaar verandering52.23%
Verandering sinds IPO279.12%

Recent nieuws en updates

Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Sep 29
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Sep 01
Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Aug 18
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 05
Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Jul 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Recent updates

Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Sep 29
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Sep 01
Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Aug 18
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 05
Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Jul 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?

Jun 24
Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Jun 03
Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Apr 28
Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Apr 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Mar 04
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
User avatar

Expansion Into Tier 2 And Tier 3 Towns Will Enhance Access To Diagnostic Services In India

Government health spending and rising NCD prevalence are likely to boost Dr. Lal PathLabs' patient volumes and revenues.

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Feb 03
Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Jan 16
Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jan 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Rendement voor aandeelhouders

LALPATHLABIN HealthcareIN Markt
7D-2.1%-0.4%1.5%
1Y-10.5%21.4%-4.7%

Rendement versus industrie: LALPATHLAB presteerde slechter dan de Indian Healthcare -sector, die het afgelopen jaar een rendement van 21.4 % opleverde.

Rendement versus markt: LALPATHLAB presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van -4.7 % opleverde.

Prijsvolatiliteit

Is LALPATHLAB's price volatile compared to industry and market?
LALPATHLAB volatility
LALPATHLAB Average Weekly Movement3.7%
Healthcare Industry Average Movement4.9%
Market Average Movement5.2%
10% most volatile stocks in IN Market8.3%
10% least volatile stocks in IN Market3.2%

Stabiele aandelenkoers: LALPATHLAB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van LALPATHLAB is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
19494,980Shankha Banerjeewww.lalpathlabs.com

Dr. Lal PathLabs Limited exploiteert laboratoria voor het uitvoeren van pathologisch onderzoek in India en daarbuiten. Het bedrijf biedt pathologische onderzoeken van verschillende takken van biochemie, hematologie, histopathologie, microbiologie, elektroforese, immunochemie, immunologie, virologie, cytologie en andere pathologische en radiologische onderzoeken. Het biedt ook trainingsprogramma's aan.

Dr. Lal PathLabs Limited Samenvatting

Hoe verhouden de winst en inkomsten van Dr. Lal PathLabs zich tot de beurswaarde?
LALPATHLAB fundamentele statistieken
Marktkapitalisatie₹261.20b
Inkomsten(TTM)₹5.13b
Inkomsten(TTM)₹25.29b
50.9x
Koers/Winstverhouding
10.3x
P/S-verhouding

Is LALPATHLAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LALPATHLAB resultatenrekening (TTM)
Inkomsten₹25.29b
Kosten van inkomsten₹10.62b
Brutowinst₹14.67b
Overige uitgaven₹9.54b
Inkomsten₹5.13b

Laatst gerapporteerde inkomsten

Jun 30, 2025

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)61.45
Brutomarge57.99%
Nettowinstmarge20.29%
Schuld/Eigen Vermogen Verhouding7.1%

Hoe presteerde LALPATHLAB op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.8%
Huidig dividendrendement
39%
Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2025/10/04 21:39
Aandelenkoers aan het einde van de dag2025/10/03 00:00
Inkomsten2025/06/30
Jaarlijkse inkomsten2025/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Dr. Lal PathLabs Limited wordt gevolgd door 52 analisten. 23 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Ashwin MehtaAmbit Capital
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital